latrepirdine
Small moleculeexperimental
Latrepirdine is an antihistamine drug which has been used clinically in Russia since 1983. — Wikipedia
Clinical trial activity
28 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
16
Phase 3
10
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00377715)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1- Mol. weight
- 319.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLatrepirdine ↗
- ChEMBLCHEMBL589390 ↗
Also known as
- 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)-ethyl)-1h-pyrid(4,3b)indole
- dimebolin
- dimebon
- dimebon
- dimebon
- dimebon
- dimebone
- latrepirdine
- latrepirdine
- latrepirdine
- latrepirdine
- pf01913539
- pf 01913539
- pf-01913539
- pf-01913539
- pf-01913539
- pf1913539
- pf 1913539
- pf-1913539
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06292351 | Phase 2 | Dec 27, 2023 | Bigespas LTD |
| NCT01066481 | Phase 2 | Apr 1, 2010 | Pfizer |
| NCT01152216 | Phase 3 | Apr 1, 2010 | Medivation, Pfizer |
| NCT01066546 | Phase 3 | Apr 1, 2010 | Medivation, Pfizer |
| NCT01085266 | Phase 3 | Feb 1, 2010 | Medivation, Pfizer |
| NCT00975481 | Phase 1 | Oct 1, 2009 | Medivation, Pfizer |
| NCT00990613 | Phase 1 | Oct 1, 2009 | Medivation, Pfizer |
| NCT00988624 | Phase 1 | Oct 1, 2009 | Medivation, Pfizer |
| NCT00954590 | Phase 3 | Oct 1, 2009 | Medivation, Pfizer |
| NCT00912288 | Phase 3 | Sep 1, 2009 | Medivation, Pfizer |
| NCT00939783 | Phase 3 | Sep 1, 2009 | Medivation, Pfizer |
| NCT00931073 | Phase 1 | Jul 1, 2009 | Medivation, Pfizer |
| NCT00920946 | Phase 3 | Jul 1, 2009 | Medivation, Pfizer |
| NCT00907322 | Phase 1 | Jun 1, 2009 | Medivation, Pfizer |
| NCT00829374 | Phase 3 | Mar 1, 2009 | Medivation, Pfizer |
| NCT00838110 | Phase 3 | Feb 1, 2009 | Medivation, Pfizer |
| NCT00831532 | Phase 1 | Feb 1, 2009 | Medivation, Pfizer |
| NCT00825084 | Phase 1 | Feb 1, 2009 | Medivation, Pfizer |
| NCT00824590 | Phase 1 | Feb 1, 2009 | Medivation, Pfizer |
| NCT00827034 | Phase 1 | Feb 1, 2009 | Medivation, Pfizer |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medivation | For profit | 26 | 11 | 3 | 2005 |
| Pfizer | For profit | 21 | 16 | 3 | 2008 |
| Huntington Study Group | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Rochester | Academic/Hospital | 2 | 0 | 1 | 2006 |
| Bigespas LTD | For profit | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1